AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data

 
• By Alaric DeArment
AstraZeneca and Merck are closer to snagging a first-line prostate cancer label for Lynparza • Source: Shutterstock

More from Anticancer

More from Therapeutic Category